# NATROX® Wound Care

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/natrox-wound-care

- Industry: Medical Devices & Equipment
- Headquarters: Cambridge, UK
- Website: www.natroxwoundcare.com
- Total disclosed funding: $46M
- Latest round: Series C (Dec 2, 2024)
- Investors on record: 6

## About

Natrox® Wound Care, based in the UK, specializes in innovative wound care technologies, focusing on Continuous Topical Oxygen Therapy (cTOT) to enhance healing processes for chronic wounds, thereby significantly improving patient recovery outcomes.Founded in 2003 in Cambridge, UK, Inotec AMD Limited focuses on advanced wound care solutions. The firm has undergone strategic development to enhance its core offerings. In 2021, the company successfully secured GBP 26.00 mn in its SERIES C funding round, attracting investments from Amadeus Capital Partners, Meltwind Advisory, Puhua Capital, and Wealth Club. The total amount raised by the company now stands at GBP 26.00 mn, with a total of 8 funding deals completed. The current CEO is Craig Kennedy, who has a background in medical technology leadership.Natrox® specializes in advanced wound care technologies, particularly focusing on their flagship product, NATROX® O2, which delivers Continuous Topical Oxygen Therapy (cTOT). This innovative therapy is designed to facilitate wound healing in both chronic and non-healing wounds by providing supplemental oxygen to the affected areas, promoting tissue regeneration and accelerating recovery. Additionally, the NATROX® IQ digital platform enhances wound management efficiency by offering clinicians tools for consistent wound measurements and automated data capture. Natrox® serves a diverse client base that includes healthcare professionals, hospitals, and outpatient clinics across global markets including the UK, US, South Korea, and various European countries, addressing the needs of patients suffering from chronic wounds such as diabetic foot ulcers.In 2017, Natrox® reported a revenue of GBP 352,109.2 and an EBITDA of GBP -2,686,950.7. The revenue model is primarily structured around the sales of topical oxygen therapy devices and digital management solutions to healthcare providers through direct-to-consumer transactions and partnerships with healthcare institutions and distributors.Natrox® plans to expand its product offerings by introducing new advanced wound care solutions aimed at addressing a broader range of wound types by the end of 2024. The company is also targeting expansion into new markets, specifically aiming to enter the Asian market, including Japan and China, by mid-2025. The recent funding of GBP 26.00 mn will be utilized to support these product developments and market expansion efforts, enhancing Natrox®'s capacity to fulfill the growing demand for effective chronic wound management solutions.

## Funding rounds

- Series C, Dec 2, 2024, $34M — Amadeus Capital Partners, Puhua Capital, Wealth Club, Meltwind Advisory
- Series C, Feb 5, 2021, $12M — Amadeus Capital Partners, Wealth Club
- Series A, Sep 24, 2012, $0.3M — Cambridge Enterprise, Parkwalk Advisors

## Investors

- Cambridge Enterprise — Series A
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Series A
- Amadeus Capital Partners (https://capitalatlas.ai/funds/amadeus-capital-partners) — Series C
- Wealth Club — Series C
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series C
- Meltwind Advisory (https://capitalatlas.ai/funds/meltwind-advisory) — Series C